ROVI’s R&D projects are focused towards the glycomics and ISM® platforms, the latter of which is ROVI’s proprietary drug-release system and has the objective of improving patient adherence to treatment. The most advanced study is that of Risperidone-ISM®, a second-generation antipsychotic medicine.

In the glycomics area, which forms part of the Company’s origins, ROVI has devoted considerable effort and investment to developing new heparin derivative-based antithrombotic products. In this respect, in March 2017, ROVI successfully completed the decentralized procedure to apply for authorization to market a low-molecular-weight heparin in twenty-six European Union countries.

English
Read time: 1 min